Ruxolitinib as a Novel Therapeutic Option for Poor Prognosis T-LBL Pediatric Patients

SIMPLE SUMMARY: Current treatment protocols for pediatric patients with T-Lymphoblastic lymphoma (T-LBL) allow the achievement of a complete remission in around 85% of T-LBL pediatric patients; however the overall survival rate of second-line treatments for patients with progressive disease or relap...

Descripción completa

Detalles Bibliográficos
Autores principales: Veltri, Giulia, Silvestri, Chiara, Gallingani, Ilaria, Sandei, Max, Vencato, Sara, Lovisa, Federica, Cortese, Giuliana, Pillon, Marta, Carraro, Elisa, Bresolin, Silvia, Biffi, Alessandra, Basso, Giuseppe, Accordi, Benedetta, Mussolin, Lara, Serafin, Valentina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8345121/
https://www.ncbi.nlm.nih.gov/pubmed/34359628
http://dx.doi.org/10.3390/cancers13153724

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8345121/
https://www.ncbi.nlm.nih.gov/pubmed/34359628
http://dx.doi.org/10.3390/cancers13153724

Ejemplares similares